The current earnings forecast score of Agenus Inc is 8.00, ranking 168 out of 386 in the Biotechnology & Medical Research industry. The average price target is 8.00, with a high of 23.00 and a low of 6.00.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
19.000
Target Price
+217.73%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Agenus Inc
AGEN
2
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Agenus Inc's expected revenue for the next quarter?
Agenus Inc's expected revenue is 34.00M.
What is Agenus Inc's price target?
Analysts forecast that Agenus Inc's price target is USD 8.00, with the highest forecast at USD 23.00 and the lowest forecast at USD 6.00.
How have Agenus IncAGEN's recent earnings per share performed?
The market expectation was USD 1.03, while Agenus IncAGEN's earnings per share (EPS) for the previous quarter was USD -0.31. EPS for the next quarter is expected at USD 0.05.
What is the analyst rating for Agenus Inc?
Based on the ratings of Agenus Inc's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.